CORE LABORATORIES INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 16.96 USD | +0.12% |
|
-0.15% | -4.05% |
| Apr. 25 | Transcript : Core Laboratories Inc., Q1 2024 Earnings Call, Apr 25, 2024 | |
| Apr. 24 | Earnings Flash (CLB) CORE LABORATORIES Reports Q1 Revenue $129.6M, vs. Street Est of $124.5M | MT |
Summary
- The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.
Strengths
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- The company's earnings growth outlook lacks momentum and is a weakness.
- The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- Over the past twelve months, analysts' consensus has been significantly revised downwards.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Business Support Services
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -4.05% | 794M | B+ | ||
| 0.00% | 6.8B | - | - | |
| -8.80% | 2.88B | B+ | ||
| -5.76% | 2.72B | - | ||
| -27.26% | 1.74B | - | - | |
| +4.53% | 1.25B | - | ||
| -5.60% | 1.06B | - | ||
| -5.00% | 870M | - | ||
| -12.19% | 768M | - | ||
| +2.49% | 757M | - |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
-
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
-
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- CLB Stock
- Ratings Core Laboratories Inc.
